KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to 70.11%.

  • Royalty Pharma's EBITDA Margin fell 600700.0% to 70.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 65.22%, marking a year-over-year decrease of 29100.0%. This contributed to the annual value of 57.1% for FY2024, which is 62800.0% down from last year.
  • As of Q3 2025, Royalty Pharma's EBITDA Margin stood at 70.11%, which was down 600700.0% from 36.26% recorded in Q2 2025.
  • Royalty Pharma's 5-year EBITDA Margin high stood at 130.17% for Q3 2024, and its period low was 85.31% during Q4 2022.
  • Over the past 5 years, Royalty Pharma's median EBITDA Margin value was 46.24% (recorded in 2023), while the average stood at 45.59%.
  • In the last 5 years, Royalty Pharma's EBITDA Margin tumbled by -1119600bps in 2022 and then surged by 1881400bps in 2023.
  • Royalty Pharma's EBITDA Margin (Quarter) stood at 26.65% in 2021, then tumbled by -420bps to 85.31% in 2022, then surged by 221bps to 102.82% in 2023, then crashed by -41bps to 60.9% in 2024, then increased by 15bps to 70.11% in 2025.
  • Its EBITDA Margin stands at 70.11% for Q3 2025, versus 36.26% for Q2 2025 and 94.01% for Q1 2025.